Ontology highlight
ABSTRACT: Importance
Randomized clinical trials of cancer screening typically use cancer-specific mortality as the primary end point. The incidence of stage III-IV cancer is a potential alternative end point that may accelerate completion of randomized clinical trials of cancer screening.Objective
To compare cancer-specific mortality with stage III-IV cancer as end points in randomized clinical trials of cancer screening.Design, setting, and participants
This meta-analysis included 41 randomized clinical trials of cancer screening conducted in Europe, North America, and Asia published through February 19, 2024. Data extracted included numbers of participants, cancer diagnoses, and cancer deaths in the intervention and comparison groups. For each clinical trial, the effect of
SUBMITTER: Feng X
PROVIDER: S-EPMC11000135 | biostudies-literature | 2024 Jun
REPOSITORIES: biostudies-literature